reduce basal insulin dose when starting glp-1 receptor agonist agonists in the treatment of type 2 diabetes – state-of-the-art If you or your patient

The reconstitution process seems simple on the surface

However, these compounds have thus far not had been subjected to clinical trials, possibly because of unwanted side effects, including lower Ca 2+ transport or increased heme-oxygenase (HO-1) levels (Konorev et al., 2002)

These drugs by increasing insulin secretion and possibly, beta cell mass, decrease plasma glucose and lipids and have a secondary action to reduce food intake and bring about weight loss

JF: Investigation, Writing review & editing, Visualization, Writing original draft

Karoulia, Z., Gavathiotis, E

Identification of a new natural biflavonoids against breast cancer cells induced ferroptosis via the mitochondrial pathway